Hologic(US:HOLX)2025-07-30 20:30Financial Performance - Q3'25 GAAP revenue reached $10238 million, a 12% increase compared to Q3'24 [67] - Q3'25 Non-GAAP revenue also reached $10238 million, with a 12% increase or 04% on a constant currency basis [68] - The company's full-year 2025 revenue guidance is between $4081 million and $4091 million, representing a 13% to 15% increase [71] - Non-GAAP diluted EPS for the full year 2025 is projected to be between $423 and $426, a 37% to 44% increase [71] Segment Performance - Diagnostics revenue in Q3'25 was $4489 million, a 09% increase [69] - Breast Health revenue in Q3'25 was $3652 million, a decrease of 58% [69] - GYN Surgical revenue in Q3'25 was $1784 million, a 63% increase [69] - Skeletal Health revenue in Q3'25 was $313 million, a substantial increase of 621% [69] Strategic Positioning - The company's net debt leverage ratio is 06x, with $19 billion in cash and investments as of Q3'25 [59] - The company has deployed over $57 billion since FY20, including $36 billion on share repurchases and $21 billion on M&A [60] - The company aims to continue double-digit non-GAAP EPS growth, driven by mid-single-digit revenue growth, modest operating margin expansion, regular acquisitions, and meaningful buybacks [57]